ArticleEClinicalMedicine2025

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer.

Qiang Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.